6922 Stock Overview
A medical device company, develops, produces, and sells minimally-invasive interventional cryotherapy products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cryofocus Medtech (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.98 |
| 52 Week High | HK$19.50 |
| 52 Week Low | HK$5.00 |
| Beta | 0 |
| 11 Month Change | 1.14% |
| 3 Month Change | 25.08% |
| 1 Year Change | -53.11% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.81% |
Recent News & Updates
Recent updates
Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?
Sep 02
We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate
Jan 10Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans
Oct 03Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth
May 30Shareholder Returns
| 6922 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 10.1% | -0.3% | -1.0% |
| 1Y | -53.1% | -45.8% | -0.6% |
Return vs Industry: 6922 underperformed the Hong Kong Medical Equipment industry which returned -44% over the past year.
Return vs Market: 6922 underperformed the Hong Kong Market which returned 2.7% over the past year.
Price Volatility
| 6922 volatility | |
|---|---|
| 6922 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6922 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6922's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 392 | Jun Zhu | www.cryofocus.com |
Cryofocus Medtech (Shanghai) Co., Ltd., a medical device company, develops, produces, and sells minimally-invasive interventional cryotherapy products in the People’s Republic of China. The company develops products in the areas of vascular interventional therapy for the treatment of atrial fibrillation, hypertension, and other cardiovascular diseases; and natural orifice transluminal endoscopic surgery for the treatment of urinary, respiratory, and digestive diseases. Its products include Bladder Cryoablation System, a cryotherapy device for the treatment of non-muscle-invasive bladder cancer; pulmonary nodule localization needle for CT-guided localization of lung nodules; endoscopic clip for anastomosis for the closure of soft tissue in digestive tract; and laparoscopic single port multi-channel access platform for laparoscopic surgery.
Cryofocus Medtech (Shanghai) Co., Ltd. Fundamentals Summary
| 6922 fundamental statistics | |
|---|---|
| Market cap | HK$1.91b |
| Earnings (TTM) | -HK$116.47m |
| Revenue (TTM) | HK$45.50m |
41.9x
P/S Ratio-16.4x
P/E RatioIs 6922 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6922 income statement (TTM) | |
|---|---|
| Revenue | CN¥41.51m |
| Cost of Revenue | CN¥9.82m |
| Gross Profit | CN¥31.70m |
| Other Expenses | CN¥137.95m |
| Earnings | -CN¥106.25m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 76.35% |
| Net Profit Margin | -255.97% |
| Debt/Equity Ratio | 15.9% |
How did 6922 perform over the long term?
See historical performance and comparison